目的 探討痰熱清注射液聯(lián)合復(fù)方二氯醋酸二異丙胺注射液治療膽汁淤積性肝病的臨床療效。方法 選取2016年1月—2017年6月樂山市人民醫(yī)院收治的膽汁淤積性肝病患者96例為研究對象，采取隨機數(shù)字表法將患者分為對照組和治療組，每組各48例。對照組靜脈滴注復(fù)方二氯醋酸二異丙胺注射液，80 mg加入5%葡萄糖液250 mL中，1次/d。治療組在對照組基礎(chǔ)上靜脈滴注痰熱清注射液，20 mL加入5%葡萄糖注射液250 mL中，1次/d。兩組患者均連續(xù)治療1個月。觀察兩組的臨床療效，比較兩組肝功能指標(biāo)、肝纖維化指標(biāo)和黃疸消退情況。結(jié)果 治療后，對照組和治療組的總有效率分別為91.67%、100.00%，兩組比較差異具有統(tǒng)計學(xué)意義（P < 0.05）。治療后，兩組血清總膽紅素（TBiL）、結(jié)合膽紅素（DBiL）、γ-谷氨酰轉(zhuǎn)移酶（GGT）、堿性磷酸酶（ALP）、丙氨酸氨基轉(zhuǎn)移酶（ALT）水平均顯著下降，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P < 0.05）；且治療組這些肝功能指標(biāo)明顯低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P < 0.05）。治療后，兩組透明質(zhì)酸（HA）、層黏連蛋白（LN）、Ⅲ型前膠原（PCⅢ）、Ⅳ型膠原（Ⅳ-C）水平均顯著下降，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P < 0.05）；且治療組這些肝纖維化指標(biāo)明顯低于對照組，兩組比較差異具具有統(tǒng)計學(xué)意義（P < 0.05）。治療10、20、30 d后，治療組黃疸消退情況明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P < 0.05）。結(jié)論 痰熱清注射液聯(lián)合復(fù)方二氯醋酸二異丙胺注射液治療膽汁淤積性肝病具有較好的臨床療效，可改善肝功能和肝纖維化，有利于黃疸消退，安全性較好，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Tanreqing Injection combined with Compound Diisopropylamine Dichloroacetate Injection in treatment of cholestasis liver disease. Methods Patients (96 cases) with cholestasis liver disease in the People's Hospital of Leshan from January 2016 to June 2017 were randomly divided into control and treatment groups, and each group had 48 cases. Patients in the control group were iv administered with Compound Diisopropylamine Dichloroacetate Injection, 80 mg added into 5% glucose solution 250 mL, once daily. Patients in the treatment group were iv administered with Tanreqing Injection on the basis of the control group, 20 mL added into 5% glucose solution 250 mL, once daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and liver function indexes, liver fibrosis indexes, and jaundice regression in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 91.67% and 100.00%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of TBiL, DBiL, GGT, ALP, and ALT in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the liver function indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of HA, LN, PCⅢ, and Ⅳ-C in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the liver fibrosis indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment for 10, 20, and 30 d, the jaundice regression in the treatment group was significantly better than that in the control group, and there was difference between two groups (P < 0.05). Conclusion Tanreqing Injection combined with Compound Diisopropylamine Dichloroacetate Injection has clinical curative effect in treatment of cholestasis liver disease, can improve live function and liver fibrosis, conducive to jaundice regression, with good safety, which has a certain clinical application value.